The REWIND and SUSTAIN-6 trials consistently highlighted the cardiovascular benefits of GLP-1 RAs, particularly in reducing stroke risk through their anti-inflammatory and atherosclerosis-reducing properties [12,14]. Here, GLP1R is linked to Stroke.